Powered by HCR Technology

The NISH Probe Portfolio is a library of ready-to-use RNA in situ hybridization (RNA-ISH) research probes for the NeoPATH Pro automated staining platform. In this context, researchers study gene expression, biomarker localization, and tissue-resident RNA across academic, biopharma, and contract research settings. They use RNA-ISH to map RNA targets directly within FFPE tissue sections. As a result, spatial information at the cellular level is retained.

Each probe uses Hybridization Chain Reaction (HCR™) chemistry. Importantly, the dual-probe (split-initiator) design requires two adjacent probes to bind the same target before signal amplification can begin. Subsequently, a probe-bound initiator drives hairpin polymerization. This process generates detectable signal at the target site. In addition, the portfolio runs as a chromogenic assay in DAB or Fast Red. It does not require a protease digestion step. Moreover, it supports both focused single-target studies and multiplex RNA-ISH panels.

Furthermore, the portfolio spans a broad menu of RNA targets for research use. These include categories such as viral RNA and immunoglobulin light chain RNA. Meanwhile, additional research targets continue to be added over time. In parallel, Empire Genomics develops each probe specifically for the NeoPATH Pro automated workflow. Therefore, NISH protocols are run on the same platform as immunohistochemistry, traditional FISH, and chromogenic ISH. As a result, the NeoPath Pro supports research applications such as gene expression mapping, biomarker characterization, viral host interaction studies, and target validation.

NISH Probes, NISH Detection Kits, and NISH Chromogens are labeled Research Use Only. Not for use in Diagnostic Procedures.